About Prostatype Genomics

Prostatype Genomics is the trusted provider of the Prostatype Genomic Classifier, which is specially designed for patients with localized prostate cancer. Our highly accurate test helps patients and healthcare professionals make well-informed treatment decisions. By providing a personalized assessment of cancer aggressiveness, we can significantly reduce the over and under-treatment, which enhances the quality of life but also saves valuable resources for the healthcare industry.

Our Mission, Our Vision, and Our Commitment

Our mission is to elevate the quality of life and provide peace of mind to those battling prostate cancer.

Our vision is to empower doctors and patients with unwavering confidence in their treatment decisions.

Our commitment to excellence drives us to offer well-validated genomic tests that accurately and precisely guide the most effective therapy for patients while reducing healthcare costs.

Our goal is to establish Prostatype as the leading genomic test for men with localized prostate cancer.

Company History

Prostatype Genomics AB, a spin-off from Cancer Center Karolinska (Karolinska Institute, Stockholm, Sweden), was founded in 2007 with a mission to turn research findings into clinical applications. 15 years of dedicated research on prostate cancer genomics has culminated in the development of the Prostatype® Genomic Classifier which is now clinically validated and market-ready. This powerful test provides invaluable decision support for healthcare professionals in selecting the best treatment for patients with localized prostate cancer.

2020 - 2021
Presentation of external validation study
  • Presentation of external validation study from Skåne University Hospital at EAU (European Association of Urology).
  • Completion of a Taiwanese validation study of 50 patients.
  • Explorative Uppsala study completed during Q3 2020. Abstract finalized Q4 2020.
  • German and Spanish distribution agreements signed.
  • Sales start in Taiwan and Spain
2022
Initiated discussions with Chinese distributors
  • Initiate discussions with Chinese distributors.
  • European validation studies initiated.
2023
IIdentification and agreement reached with distributor/partner in Taiwan
  • Identification and agreement reached with distributor/partner in Taiwan
  • Sales start in UK, Norway and Spain
  • Validation study initiated in Spain.
  • Validation study completed in Taiwan

Senior Management Team, Prostatype Genomics, Inc in the USA

Steven Gaal

President

Steven brings 19 years of successful commercial experience in molecular diagnostics and oncology. Previously, he served as Commercial Director of Skyline Diagnostics, a Dutch-owned San Diego based-CAP/CLIA genomics laboratory providing LDT assays for melanoma and multiple myeloma prognosis to help guide treatment decisions. At MDxHealth he was instrumental in the launch and clinical adoption the company’s tissue and urine-based LDT tests in urology and oncology. He has also held senior leadership roles at US LABS (acquired by LabCorp) and other national laboratories.

Gerald Andriole, MD

Gerald Andriole, MD

Chief Medical Officer

Dr. Andriole was most recently a Professor in the Department of Urology and Director of the Brady Urological Institute in the National Capital Region of Johns Hopkins University. Previously, he was the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri. Dr. Andriole received his medical degree from Jefferson Medical College, Philadelphia, Pennsylvania. He completed urology residency at Brigham and Women’s Hospital and Harvard Medical School, Boston, MA. He then received specialty training in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Dr. Andriole has over 35 years of consistent contributions in prostate cancer prevention, screening and treatment research.  Dr. Andriole has been the recipient of numerous awards including the outstanding achievement award from the Urologic Oncology Branch of the National Cancer Institute, the Distinguished Clinician Award from Washington University in St. Louis and the Richard Williams Award for Prostate Cancer Research Excellence from the American Urologic Association Urology Care Foundation.

Emelie Berglund, PhD, MSc

Emelie Berglund, PhD, MSc

Chief Technology Officer

Dr. Berglund brings a decade of scientific experience in molecular diagnostics, specializing in prostate cancer. Previously, Dr. Berglund served as a Senior Scientist and project manager at iCellate Medical AB where she focused on the development of a next generation circulating tumor cell (CTC)-based platform for detection and comprehensive biomarker analysis to improve precision oncology. Dr. Berglund earned a PhD and a MSc in Biotechnology at the KTH Royal Institute of Technology in Stockholm, Sweden.

Corporate Leadership Team, Prostatype Genomics AB in Sweden

Fredrik Persson

Fredrik Rickman

CEO
Anders Koch

Anders Koch

CFO
Emelie Berglund, PhD, MSc

Emelie Berglund

Chief Technology Officer
Albin Bremer

Albin Bremer

Sales Manager Europe
Katarina Sjöberg

Katarina Sjöberg

Head of Regulatory Affairs and Quality Assurance

Fredrik Rickman

CEO

About:
B.Sc in Business Administration and Economics, University of Lund. 30 yrs of international life science industry experience in leading positions with focus on operational and organizational growth.

Other assignments:
Stradis Med Nordics AB; Chairman of the Board

Anders Koch

CFO

CFO since December 2023.

About:
M.Sc. in Economics and Business, Stockholm University. Deep experience in financial reporting and managerial finance cemented from 13 years as authorized public accountant with PwC followed by 13+ years as CFO, Financial Controller and member of the Executive Management teams in the Telecom and Digital Media Production industries.

The position is part-time.

Other assignments:
Carisus Consulting AB; Founder and owner

Emelie Berglund

Chief Technology Officer

About:
PhD in Biotechnology from KTH (Royal Institute of Technology) in Stockholm. Emelie has 10 yrs of experience working in research within the prostate cancer field, including 2 years of private sector experience working in diagnostic product development.

Albin Bremer

Sales Manager Europe

About:
I am an active professional with over 23 years of experience in the pharmaceutical industry, primarily focused on urology. For the past two years, I’ve been with Prostatype, dedicated to advancing precision medicine in prostate cancer care. My mission is to contribute to reducing both overtreatment and undertreatment in this critical field. Outside of work, I enjoy spending my time by the sea or exploring the mountains.

Katarina Sjöberg

Head of Regulatory Affairs and Quality Assurance

About:
30 years of experience working in life sciences, holding various positions and responsibilities. 14 of those years as QA Manager, in different QA/RA organizations.

Board of Directors, Prostatype Genomics AB

Anders Lundberg

Anders Lundberg

Chairman of the Board, Independent
Dr. Michael Häggman

Dr. Michael Häggman

Independent Board Member
Jörgen Dahlström

Jörgen Dahlström

Independent Board Member
Håkan Englund

Håkan Englund

Independent Board Member
Mattias Prage

Mattias Prage

Independent Board Member

Anders Lundberg

Chairman of the Board, Independent

About:
M.Sc. Mechanical Engineering, KTH, Stockholm, Sweden. Founder and CEO of a telecom equipment supplier recognized by the market and later brought to a successful IPO in 2011 on the MID-CAP list OMX-Nasdaq [TRMO:Transmode]

Other assignments:
AJ Lundberg Kapitalförvaltning AB; Board member
Sollentunafastigheter 2 AB; Deputy board member
Sollentunahem AB; Deputy board member

Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Dr. Michael Häggman

Independent Board Member

About:
M.D, Ph.D. associate professor, department of Urology, Akademiska University Hospital, Uppsala, Sweden. More than 30 years of experience practicing as urologist with an extensive national and international network among urologists.

Other assignments:
Skrotum Kommanditbolag; General partner
Kardinaltalet AB; Deputy board member

Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Jörgen Dahlström

Independent Board Member

About:
Holds a Ph.D. in Immunology and a M.Sc. in Biochemistry from Uppsala University and an Executive MBA. Jörgen is the CEO of Mercodia, a Swedish based Life Science company and has more than 25 years’ experience from the international Life Science industry. The main focus has been on developing and executing company strategies for commercialization and business growth.  He has held several senior leadership positions including CEO of Svar Life Science. Jörgen has an extensive strategic and commercial experience and a wide international network.

Independent in relation to Prostatype Genomics, its senior management and major shareholders

Håkan Englund

Independent Board Member

About:
Various courses in economics and chemistry from Uppsala University, Sweden. Courses in polymer technology at Royal Institute of Technology in Stockholm, Sweden. CEO and owner, JDS Invest. More than 30 years of operational and investment experience from life science and health care industry with focus on commercialization and business development. Håkan has held several leading management positions at Pharmacia Biotech and Phadia and has during his career developed extensive national and international relevant networks.

Other assignments:
Antrad Medical AB; Board member
SecureAppbox AB; Chairman of the Board

Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Mattias Prage

Independent Board Member

About:
Lawyer and partner at Advokatfirman Lindahl, specialized in corporate law, financing and commercial contracts.

Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Join Our Team

At Prostatype Genomics, we offer equal employment opportunities regardless of race, color, religion, sex, sexual orientation, gender identity, national origin, or veteran status. We also do not discriminate against individuals with disabilities. As a leading healthcare company, we provide excellent career and financial opportunities. If you are interested in joining our team, please contact our Human Resources Department.

Current Openings

There are currently no open positions

Before Deciding Know His Prostatype!​